Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
72 studies found for:    Cobicistat[TREATMENT] AND HIV [CONDITION]
Show Display Options
Rank Status Study
21 Completed
Has Results
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: PI;   Drug: RTV;   Drug: FTC/TDF;   Drug: Stribild
22 Active, not recruiting An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal
Condition: HIV-2 Infection
Intervention: Drug: Stribild (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF) 1 tablet daily X 48 weeks
23 Not yet recruiting Early ART to Limit Infection and Establishment of Reservoir
Condition: HIV-1 Infection
Intervention: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy
24 Active, not recruiting Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet
Condition: HIV
Intervention: Drug: (FDC) ELV/COBI/FTC/TDF
25 Completed
Has Results
Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults
Conditions: HIV-1;   HIV Infections;   Acquired Immunodeficiency Syndrome
Interventions: Drug: E/C/F/TAF;   Drug: DRV;   Drug: Pre-existing ARV regimen
26 Completed A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat
Conditions: Hepatitis C;   HIV
Interventions: Drug: Daclatasvir;   Drug: Atazanavir;   Drug: Ritonavir;   Drug: Cobicistat
27 Active, not recruiting Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants
Condition: Human Immunodeficiency Virus Type 1
Interventions: Drug: D/C/F/TAF;   Drug: Boosted Protease Inhibitor (bPI);   Drug: FTC/TDF
28 Completed
Has Results
Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: E/C/F/TDF;   Drug: E/C/F/TAF Placebo;   Drug: E/C/F/TAF;   Drug: E/C/F/TDF Placebo
29 Recruiting ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment
Condition: HIV Infection
Interventions: Drug: ABX464;   Drug: Placebo
30 Completed
Has Results
Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Condition: HIV-1 Infection
Interventions: Drug: COBI;   Drug: RTV;   Drug: ATV;   Drug: FTC/TDF;   Drug: COBI placebo;   Drug: RTV placebo
31 Active, not recruiting
Has Results
Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: E/C/F/TAF;   Drug: E/C/F/TDF;   Drug: E/C/F/TDF Placebo;   Drug: E/C/F/TAF Placebo
32 Active, not recruiting
Has Results
Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: E/C/F/TAF;   Drug: E/C/F/TDF;   Drug: E/C/F/TDF Placebo;   Drug: E/C/F/TAF Placebo
33 Recruiting Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years
Condition: HIV-1 Infection
Interventions: Drug: E/C/F/TAF;   Drug: TDF;   Drug: FTC;   Drug: FTC/TDF;   Drug: 3TC;   Drug: Third agent
34 Completed
Has Results
Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: COBI;   Drug: RTV;   Drug: ATV;   Drug: FTC/TDF;   Drug: COBI placebo;   Drug: RTV placebo
35 Active, not recruiting Renal Integrase Study
Condition: HIV
Interventions: Drug: Stribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat);   Drug: Isentress® (Raltegravir 400 mg)1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet;   Drug: Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir)
36 Completed Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study
Conditions: Hepatitis C Infection;   HIV Infection
Intervention: Drug: Sofosbuvir, Ribavirin, and Stribild
37 Completed
Has Results
D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: D/C/F/TAF;   Drug: DRV;   Drug: COBI;   Drug: FTC/TDF;   Drug: D/C/F/TAF Placebo;   Drug: DRV Placebo;   Drug: COBI Placebo;   Drug: FTC/TDF Placebo
38 Recruiting Pharmacokinetic Effect of Evotaz/Microgynon Co-administration
Condition: HIV
Interventions: Drug: Microgynon 30®;   Drug: Evotaz®
39 Active, not recruiting Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents
Condition: HIV
Intervention: Drug: E/C/F/TAF
40 Active, not recruiting
Has Results
Safety and Efficacy of E/C/F/TDF (Stribild®) Versus RTV-Boosted ATV Plus FTC/TDF (Truvada®) in HIV-1 Infected, Antiretroviral Treatment-Naive Women
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: E/C/F/TDF;   Drug: RTV;   Drug: ATV;   Drug: FTC/TDF;   Drug: E/C/F/TDF Placebo;   Drug: RTV Placebo;   Drug: ATV Placebo;   Drug: FTC/TDF Placebo;   Drug: E/C/F/TAF

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.